Evaluation of anti-pruritus effect of melatonin in liver disease

Evaluation of anti-pruritus effect of melatonin on patient with liver disease: a randomized clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180519039718N1

Enrollment

Registered

2018-08-20

Start date

2018-08-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus induced by liver disease. Liver disease, unspecified

Interventions

Intervention group: patients in this group are going to receive 2 capsules of melatonin 5 mg, made by Super Natural Company of Canada, at night for 2 weeks a long with other anti-pruritus treatments.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients equal and more18 years old Obtain informed consent Patients with pruritus induced by liver disease

Exclusion criteria

Exclusion criteria: Patients with epilepsy or undertreated with antiepileptic drugs Pregnancy or lactation Any skin disorder with itching(eczema, dermatitis) New medicine treating itching has been started during the past 4 weeks Patients with renal disease at stage 5 or on dialysis

Design outcomes

Primary

Measure	Time frame
Severity of pruritus. Timepoint: At the baseline (before intervention) and at the end of second, fourth and sixth weeks of intervention. Method of measurement: 12-Item Pruritus Severity Scale, visual analog scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAyda Esmaeili

Tehran University of Medical Sciences

a_esmaeili@razi.tums.ac.ir+98 21 8835 4275

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026